• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Reply to: "Glecaprevir/pibrentasvir + sofosbuvir + ribavirin offers high cure rate for hepatitis C virus retreatment in real-world settings".

作者信息

Dietz Julia, Sarrazin Christoph

机构信息

Department of Internal Medicine 1, University Hospital, Goethe University, Frankfurt, Germany; German Center for Infection Research (DZIF), External Partner Site Frankfurt, Germany.

Department of Internal Medicine 1, University Hospital, Goethe University, Frankfurt, Germany; German Center for Infection Research (DZIF), External Partner Site Frankfurt, Germany; Medizinische Klinik 2, St. Josefs-Hospital, Wiesbaden, Germany.

出版信息

J Hepatol. 2021 Jul;75(1):254-255. doi: 10.1016/j.jhep.2021.04.017. Epub 2021 Apr 20.

DOI:10.1016/j.jhep.2021.04.017
PMID:33892009
Abstract
摘要

相似文献

1
Reply to: "Glecaprevir/pibrentasvir + sofosbuvir + ribavirin offers high cure rate for hepatitis C virus retreatment in real-world settings".
J Hepatol. 2021 Jul;75(1):254-255. doi: 10.1016/j.jhep.2021.04.017. Epub 2021 Apr 20.
2
Glecaprevir/pibrentasvir + sofosbuvir + ribavirin offers high cure rate for hepatitis C virus retreatment in real-world settings.格卡瑞韦/哌仑他韦+索磷布韦+利巴韦林在真实世界环境中为丙型肝炎病毒再治疗提供了高治愈率。
J Hepatol. 2021 Jul;75(1):251-254. doi: 10.1016/j.jhep.2021.02.024. Epub 2021 Feb 27.
3
Successful ongoing retreatment with glecaprevir/pibrentasvir + sofosbuvir + ribavirin in a patient with HCV genotype 3 who failed glecaprevir/pibrentasvir with both NS3 and NS5A resistance.对于一名丙型肝炎病毒3型患者，在其接受glecaprevir/pibrentasvir治疗失败且对NS3和NS5A产生耐药性后，使用glecaprevir/pibrentasvir联合索磷布韦和利巴韦林进行成功的持续再治疗。
Clin Microbiol Infect. 2020 Sep;26(9):1266-1268. doi: 10.1016/j.cmi.2020.03.022. Epub 2020 Mar 30.
4
Sofosbuvir/Velpatasvir Plus Ribavirin Combination Therapy for Patients with Hepatitis C Virus Genotype 1a, 2a, or 3b after Glecaprevir/Pibrentasvir Therapy Failed.索磷布韦/维帕他韦联合利巴韦林治疗格卡瑞韦哌仑他韦治疗失败的 HCV 基因 1a、2a 或 3b 型患者
Intern Med. 2021 Nov 1;60(21):3441-3445. doi: 10.2169/internalmedicine.7028-21. Epub 2021 May 22.
5
[A case of HCV genotype 3b with compensated stage cirrhosis who have two times treatment-experienced with the use of glecaprevir/pibrentasvir combined with sofosbuvir and ribavirin for 16 weeks].1例丙型肝炎病毒3b基因型代偿期肝硬化患者，曾两次接受glecaprevir/pibrentasvir联合索磷布韦和利巴韦林治疗16周。
Zhonghua Gan Zang Bing Za Zhi. 2021 Dec 20;29(12):1194-1195. doi: 10.3760/cma.j.cn501113-20200526-00275.
6
Comparison of Glecaprevir/Pibrentasvir and Sofosbuvir/Ledipasvir in Patients with Hepatitis C Virus Genotype 1 and 2 in South Korea.韩国 1 型和 2 型丙型肝炎病毒患者中 Glecaprevir/Pibrentasvir 和 Sofosbuvir/Ledipasvir 的比较。
Korean J Gastroenterol. 2024 Mar 25;83(3):111-118. doi: 10.4166/kjg.2023.141.
7
NS5A-P32 deletion as a factor involved in virologic failure in patients receiving glecaprevir and pibrentasvir.NS5A-P32 缺失是导致接受 glecaprevir 和 pibrentasvir 治疗的患者病毒学失败的一个因素。
J Gastroenterol. 2019 May;54(5):459-470. doi: 10.1007/s00535-018-01543-9. Epub 2019 Jan 5.
8
Sofosbuvir, Glecaprevir, Pibrentasvir, and Ribavirin as a Rescue Therapy in Difficult-to-Treat HCV Patients.索磷布韦、格卡瑞韦、哌仑他韦和利巴韦林作为难治性丙型肝炎患者的挽救疗法
Hepatology. 2021 Oct;74(4):2304-2306. doi: 10.1002/hep.31909. Epub 2021 Jun 16.
9
[Glecaprevir/Pibrentasvir + Sofosbuvir + Ribavirin as a salvage regimen after Sofosbuvir + Velpatasvir + Voxilaprevir re-treatment failure].[格卡瑞韦/哌仑他韦+索磷布韦+利巴韦林作为索磷布韦+维帕他韦+伏西瑞韦再治疗失败后的挽救方案]
Z Gastroenterol. 2022 Jun;60(6):959-962. doi: 10.1055/a-1649-8931. Epub 2021 Oct 19.
10
Prevalence of resistance-associated substitutions and retreatment of patients failing a glecaprevir/pibrentasvir regimen.耐药相关替换的流行情况以及接受 glecaprevir/pibrentasvir 方案治疗失败的患者的再治疗。
J Antimicrob Chemother. 2020 Nov 1;75(11):3349-3358. doi: 10.1093/jac/dkaa304.